J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kearns, G. L.
Right arrow Articles by the Pediatric Pharmacology Research Unit Network,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kearns, G. L.
Right arrow Articles by the Pediatric Pharmacology Research Unit Network,

PEDIATRICS

Omeprazole Disposition in Children following Single-Dose Administration

Gregory L. Kearns, PharmD, PhD, FCP, Tommy Andersson, PhD, Laura P. James, MD, Andrea Gaedigk, PhD, Rebecca A. Kraynak, BS, Susan M. Abdel-Rahman, PharmD, Krishnaswami Ramabadran, PhD, John N. van den Anker, MD, PhD and the Pediatric Pharmacology Research Unit Network

From the Departments of Pediatrics (Dr. Kearns, Dr. Abdel-Rahman) and Pharmacology (Dr. Kearns), University of Missouri-Kansas City, Kansas City, Missouri; Division of Pediatric Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri (Dr. Kearns, Dr. Gaedigk, Dr. Abdel-Rahman); AstraZeneca LP, Wayne, Pennsylvania (Dr. Andersson, Ms. Kraynak, Dr. Ramabadran); Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas (Dr. James); Division of Pediatric Clinical Pharmacology and Toxicology, Arkansas Children's Hospital, Little Rock, Arkansas (Dr. James); Department of Pediatrics, Ohio State University, Columbus, Ohio (Dr. van den Anker); Division of Pediatric Clinical Pharmacology and Toxicology, Columbus Children's Hospital, Columbus, Ohio (Dr. van den Anker); and the National Institute of Health and Human Development, Bethesda, Maryland (Pediatric Pharmacology Research Unit Network).

Omeprazole is frequently used to treat gastroesophageal reflux in infants and children despite the lack of age-specific pharmacokinetic and dosing information in the approved product labeling. To address this challenge, the authors examined the potential influence of development and cytochrome P450 2C19 (CYP2C19) genotype on omeprazole disposition by conducting two pharmacokinetic (PK) studies in children and adolescents (ages 2-16 years) after a single oral 10- or 20-mg dose of the drug. Plasma omeprazole concentrations were determined by HPLC-MS from seven plasma samples obtained over a 6-hour postdose period. Pharmacokinetic parameters were determined by noncompartmental methods. Subjects were genotyped for CYP2C19 by PCRRFLP. Data were available from 37 patients (19 female), 10 of whom were <= 5 years of age. No drug-associated adverse events were observed. The numbers of functional CYP2C19 alleles per subject in the cohort were 2 (n =25),1(n = 11), and 0 (n = 1). Pharmacokinetic parameters (mean ± SD, range) were as follows: tmax (2.1 ± 1.2, 1-6 h), Cmax (331.1 ± 333.6, 20.8-885.8 ng/mL), AUC0 -> {infty} (809.5 ± 893.8, 236.9-1330.9 ng/mL•h), t1/2 (0.98 ± 0.22, 0.7-1.4 h), and CL/F (1.8 ± 1.4, 0.3-5.8 L/h/kg). Comparison of mean AUC0 -> {infty} values normalized for dose (i.e., per 1 mg/kg) between subjects with one versus two functional CYP2C19 alleles revealed no statistically significant difference. In addition, the CL/F and apparent elimination rate constant ({lambda}z) for omeprazole were not significantly different for subjects with one versus two functional CYP2C19 alleles. No association between age and CL/F, t1/2, or {lambda}z was observed. The range of t1/2 values for omeprazole was similar to those reported in adults (1-1.5 h). Conclusions: (1) in children ages 2 to 16 years receiving 10 or 20 mg of omeprazole as a single oral dose, the PK are quite comparable to values reported for adults, and (2) in pediatric patients who are CYP2C19 extensive metabolizers, there was no association between genotype and the pharmacokinetics of omeprazole.

Key Words: Omeprazole • pediatrics • gastroesophageal reflux • pharmacokinetics • CYP2C19 genotype

Address for reprints: Dr. Gregory L. Kearns, Professor and Chief, Division of Pediatric Pharmacology & Medical Toxicology, Children's Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108.




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
G. L. Kearns, J. Blumer, S. Schexnayder, L. P. James, K. G. Adcock, M. D. Reed, J. F. Daniel, A. Gaedigk, and J. Paul
Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents
J. Clin. Pharmacol., November 1, 2008; 48(11): 1356 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
V. M. Tsou, R. Baker, L. Book, A.-H. Hammo, E. F. Soffer, W. Wang, G. M. Comer, and Members of the 326 Study Group
Multicenter, Randomized, Double-Blind Study Comparing 20 and 40 mg of Pantoprazole for Symptom Relief in Adolescents (12 to 16 Years of Age) with Gastroesophageal Reflux Disease (GERD)
Clinical Pediatrics, October 1, 2006; 45(8): 741 - 749.
[Abstract] [PDF]

Home page
 NeoReviewsHome page
S. R. Jadcherla and C. D. Rudolph
Gastroesophageal Reflux in the Preterm Neonate
NeoReviews, February 1, 2005; 6(2): e87 - e98.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Clinical Pharmacology